UnknownNot Applicable

Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study

France250 participantsStarted 2021-07-05

Plain-language summary

This study aims to assess the incidence of atrial fibrillation (AF), documented using data recorded by an implantable Holter monitoring device (Reveal Linq, Medtronic) within 2 years after percutaneous closure of patent foramen ovale for cryptogenic stroke.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients (aged \>18 years) * with an indication for percutaneous closure of PFO due to cryptogenic stroke, with indication validated by a cardio-neurological team. * patients must provide written informed consent * patients must be affiliated to a social security regime or be a beneficiary thereof. Exclusion Criteria: * Patients under legal protection * Patients not affiliated to any social security regime * Patients within the exclusion period of another clinical trial as per the national registry of research volunteers

What they're measuring

Atrial fibrillation

Timeframe: Within 2 months after percutaneous PFO closure

Trial details

NCT IDNCT04926142

SponsorCentre Hospitalier Universitaire de Besancon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-08-21

View on ClinicalTrials.gov More Patent Foramen Ovale trials